Significance of post-progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma.

ABSTRACT:

Background and aim

Molecular-targeted therapies such as sorafenib and lenvatinib have long been used as first-line treatment for advanced hepatocellular carcinoma (aHCC). However, adverse events or limited therapeutic effects may necessitate the change to another therapeutic option, known as post-progression therapy. To investigate the significance of post-progression therapy, we analyzed the outcomes of aHCC patients following first-line molecular-targeted therapy in a real-world study.

Methods

This retrospective, multicenter study involved patients with aHCC who received sorafenib or lenvatinib as first-line therapy between January 2011 and September 2021.

Results

In total, 513 patients were analyzed: 309 treated with sorafenib and 204 with lenvatinib. The overall r

SUBMITTER: Yano Y 

PROVIDER: S-EPMC9218537 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature